261 related articles for article (PubMed ID: 12476941)
1. Increased levels of osteoprotegerin in hemodialysis patients.
Avbersek-Luznik I; Malesic I; Rus I; Marc J
Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
[TBL] [Abstract][Full Text] [Related]
2. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
3. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
[TBL] [Abstract][Full Text] [Related]
4. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
5. Serum osteoprotegerin and renal osteodystrophy.
Coen G; Ballanti P; Balducci A; Calabria S; Fischer MS; Jankovic L; Manni M; Morosetti M; Moscaritolo E; Sardella D; Bonucci E
Nephrol Dial Transplant; 2002 Feb; 17(2):233-8. PubMed ID: 11812872
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
[TBL] [Abstract][Full Text] [Related]
7. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
Grzegorzewska AE; Mlot M
Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.
Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Domenig C; Zsontsich T; Klaushofer K; Delling G; Oberbauer R
Am J Kidney Dis; 2002 Mar; 39(3):580-6. PubMed ID: 11877577
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
[TBL] [Abstract][Full Text] [Related]
11. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342
[TBL] [Abstract][Full Text] [Related]
12. Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone.
Grzegorzewska AE; Mlot-Michalska M
Adv Perit Dial; 2006; 22():203-6. PubMed ID: 16983970
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
14. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
[TBL] [Abstract][Full Text] [Related]
15. Serum leptin in dialysis renal osteodystrophy.
Coen G; Ballanti P; Fischer MS; Balducci A; Calabria S; Colamarco L; Di Zazzo G; Lifrieri F; Manni M; Sardella D; Nofroni I; Bonucci E
Am J Kidney Dis; 2003 Nov; 42(5):1036-42. PubMed ID: 14582047
[TBL] [Abstract][Full Text] [Related]
16. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure.
Kazama JJ; Shigematsu T; Yano K; Tsuda E; Miura M; Iwasaki Y; Kawaguchi Y; Gejyo F; Kurokawa K; Fukagawa M
Am J Kidney Dis; 2002 Mar; 39(3):525-32. PubMed ID: 11877571
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
18. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
19. OPG, RANK-L, bone metabolism, and BMD in patients on peritoneal dialysis and hemodialysis.
Wittersheim E; Mesquita M; Demulder A; Guns M; Louis O; Melot C; Dratwa M; Bergmann P
Clin Biochem; 2006 Jun; 39(6):617-22. PubMed ID: 16530745
[TBL] [Abstract][Full Text] [Related]
20. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
